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Abstract
Introduction Estrogen and estrogen receptor (ER)-mediated
signaling are crucial for the etiology and progression of human
breast cancer. Attenuating ER activities by natural products is a
promising strategy to decrease breast cancer risk. We recently
discovered that the pyranocoumarin compound decursin and its
isomer decursinol angelate (DA) have potent novel
antiandrogen receptor signaling activities. Because the ER and
the androgen receptor belong to the steroid receptor
superfamily, we examined whether these compounds affected
ER expression and signaling in breast cancer cells.
Methods We treated estrogen-dependent MCF-7 and
estrogen-independent MDA MB-231 human breast cancer cells
with decursin and DA, and examined cell growth, apoptosis, and
ERα and ERβ expression in both cell lines – and, in particular,
estrogen-stimulated signaling in the MCF-7 cells. We compared
these compounds with decursinol to determine their structure-
activity relationship.
Results Decursin and DA exerted growth inhibitory effects on
MCF-7 cells through G1  arrest and caspase-mediated
apoptosis. These compounds decreased ERα in MCF-7 cells at
both mRNA and protein levels, and suppressed estrogen-
stimulated genes. Decursin and the pure antiestrogen
Faslodex™ exerted an additive growth inhibitory effect on MCF-
7 cells. In MDA MB-231 cells, these compounds induced cell-
cycle arrests in the G1 and G2 phases as well as inducing
apoptosis, accompanied by an increased expression of ERβ. In
contrast, decursinol, which lacks the side chain of decursin and
DA, did not have these cellular and molecular activities at
comparable concentrations.
Conclusion The side chain of decursin and DA is crucial for
their anti-ER signaling and breast cancer growth inhibitory
activities. These data provide mechanistic rationales for
validating the chemopreventive and therapeutic efficacy of
decursin and its derivatives in preclinical animal models of
breast cancer.
Introduction
Breast cancer is the most commonly diagnosed nonskin malig-
nancy among American women, accounting for approximately
32% (211,000 cases) of all new cancer cases per year [1]. It
is the second leading cause of cancer death in US women,
claiming the lives of 41,000 annually. The female hormone
estrogen and its classic intracellular receptor – estrogen
receptor (ER) alpha – are crucial for breast development and
are also causally linked to the etiology and progression of
breast cancer and gynecologic cancers [2-4]. The genomic
effects of estrogen are principally mediated by ERα [3], the
activity of which is counter-balanced by the inhibitory ERβ
[3,5-8].
Estrogen, through its ERα-mediated genomic effects and non-
genomic effects, induces breast epithelial cell proliferation and
AR = androgen receptor; bp = base pairs; ELISA = enzyme-linked immunosorbent assay; ER = estrogen receptor; ERE = estrogen-response element; 
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suppresses apoptosis [3,9]. Since estrogen activity can be
modulated by agonists as well as by antagonists, compounds
that interfere with ERα function have proved useful in the treat-
ment and chemoprevention of ER-positive breast cancer [10].
In fact, the classic nonsteroidal antiestrogen tamoxifen is the
first Food and Drug Administration-approved chemopreven-
tive agent for breast cancer. Because of its partial ER agonist
activity, however, tamoxifen causes some adverse effects,
including an increase of the risk of uterine endometrial cancer
in women after prolonged use [11]; therefore women are not
allowed to use this drug for longer than 5 years. Novel agents
that target ERα signaling as well as estrogen production with-
out agonist activities will be desirable for breast cancer chem-
oprevention and treatment, and for women who have finished
the prescribed course of tamoxifen [12-15].
The root of Korean medicinal herb Angelica gigas Nakai (also
known as Cham Dang Gui) has been used in traditional Orien-
tal herbal medicine for thousands of years for treating female
afflictions and is regarded by herbalists as 'female Ginseng' for
its hemopoietic and health-promoting activities [16]. These
known medicinal properties, however, were based on using
boiling water to extract the active ingredients or chemicals. An
often underappreciated principle of herbal medicine is that
changing the extraction solvents can lead to the recovery of
different chemicals and therefore to novel medicinal and phar-
macological properties. In fact, many pyranocoumarin com-
pounds have been identified from the alcohol extract of A.
gigas Nakai [17,18] with diverse pharmacological activities
including cytotoxic action against leukemia cells [19-22], anti-
bacterial action [23], pain-killing action [24] and antimemory
loss action [25].
We recently discovered that the pyranocoumarin compound
decursin and its isomer decursinol angelate (DA) (Figure 1)
from the ethanol extract of dried A. gigas Nakai root have
potent and novel antiandrogen receptor (anti-AR) signaling
activities in vitro [26,27]. They inhibit the androgen-stimulated
translocation of the AR from the cytosol to the nucleus,
decrease the AR protein level in part through increased pro-
teasomal degradation, and suppress AR transactivation activ-
ity [26,27]. In addition, these compounds have been shown to
inhibit the growth of human leukemia cell lines and androgen-
independent prostate cancer cell lines [28], and to increase
the survival of mice carrying inoculated sarcoma cells in vivo
[29]. Because the ER and the AR belong to the steroid recep-
tor superfamily, we sought to determine whether these pyrano-
coumarin compounds exerted similar activities against ER
expression and function in breast cancer cells.
In the present article we report that decursin and DA potently
inhibit estrogen-stimulated mitogenesis at micromolar concen-
trations in the estrogen-dependent MCF-7 human breast can-
cer cells through G1 arrest and caspase-mediated apoptosis.
The effects are associated with downregulating ERα protein
abundance and transactivation functions. In addition, decursin
and the steroidal pure antiestrogen Faslodex™ (ICI 182,780 or
fulvestrant) [15,30] exert additive growth inhibitory activity in
MCF-7 cells. Furthermore, these compounds induce cell-cycle
arrest at the G1 or G2 phase and induce apoptosis in the estro-
gen-independent MDA231 human breast cancer cells,
Figure 1
Growth inhibition of MCF-7 cells by decursin Growth inhibition of MCF-7 cells by decursin. (a) Chemical structure of 
pyranocoumarin compounds isolated from Angelica gigas root. (b) 
Growth inhibitory effects of decursin on exponentially growing MCF-7 
cells (30–40% confluent) in T25 flasks. Exposure to different decursin 
concentrations (D5 μM, D20 μM, D50 μM, D100 μM) was in complete 
medium for 3 days. Results based on two separate experiments (mean 
± standard deviation). *P < 0.05, **P < 0.001 versus control. (c) Inhibi-
tion of long-term colony growth of MCF-7 cells. Sparsely seeded cells 
(~10% confluent) in six-well plates were exposed to different decursin 
concentrations (D20 μM, D50 μM, D100 μM) in the complete medium 
for 7 days. After fixation with 1% glutaraldehyde, the cells remaining 
attached were stained in situ with 0.02% crystal violet and were photo-
graphed. DMSO, dimethylsulfoxide.Available online http://breast-cancer-research.com/content/9/6/R77
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accompanied by an upregulation of ERβ. We report also the
response patterns of selected cell-cycle and mitogenic signal-
ing molecules in these two cell lines.
Materials and methods
Natural product chemicals
Decursin, DA and decursinol were extracted and purified as
described in previous publications [26,27].
Cell culture and treatments
MCF-7 cells (expressing high levels of ERα) and MDA MB-
231 cells (ERα-negative, expressing ERβ) were obtained from
the American Type Culture Collection (Manassas, VA, USA).
The MCF-7 cells were grown in Eagle's minimal essential
medium (American Type Culture Collection) supplemented
with 10 μg/ml insulin and 10% FBS (Atlanta Biologicals, Law-
renceville, GA, USA) in a humidified incubator with 5% CO2.
The MDA MB-231 cells were grown in Leibovitz's L-15
medium (American Type Culture Collection) supplemented
with 10% FBS (Atlanta Biologicals) in a humidified incubator
with atmospheric CO2. When cells were ~50% confluent
(usually 2 days after plating for MCF-7 cells and 3 days after
plating for MDA MB-231 cells), the medium was changed and
treatment with compounds was started in fresh medium.
In experiments where estrogen stimulation was required, the
spent medium was removed and the adherent MCF-7 cells
were rinsed gently with phenol-red free improved minimal
essential medium (PRF-IMEM) without serum and insulin (Bio-
source, Rockville, MD, USA) to remove leftover estrogen. PRF-
IMEM with 5% charcoal-stripped FBS (Atlanta Biologicals)
without insulin was then added for estrogen deprivation. Estro-
gen stimulation was provided by 17β-estradiol (Sigma Chem-
ical Company, St Louis, MO, USA). Faslodex™ (ICI 182,780;
Tocris Bioscience, Avonmouth, UK) and/or an active metabo-
lite of tamoxifen, 4-hydroxytamoxifen (4-HT) (LKT Labs, St
Paul, MN, USA), were used as positive antiestrogen agents for
comparison with decursin and DA in key experiments.
Cell growth and cell death (apoptosis) assays
The effects of compounds on breast cancer cell numbers were
estimated either by counting cells with a hemacytometer or by
crystal violet staining of adherent cells. Cell-cycle analyses
were carried out with propidium iodide staining according to
Krishan's protocol [31] and flow cytometry using a FACSCal-
iber flow cytometer (Becton-Dickinson, San Jose, CA, USA).
Cell death was detected either by an ELISA kit for nucleo-
somal DNA fragmentation with an antibody sandwich assay
that detects DNA and associated histones (Roche Diagnos-
tics Corporation, Indianapolis, IN, USA) or by an immunoblot
analysis of the caspase-mediated cleavage of poly(ADP-
ribose) polymerase (PARP) as described previously [26].
Reverse transcriptase-polymerase chain reaction
Estrogen-deprived MCF-7 cells were given fresh media con-
taining decursin, DA, decursinol, Faslodex™ and 1 nM 17β-
estradiol. After exposure for 24 hours, the attached cells
underwent RNA extraction using an RNeasy kit (catalogue
number 74104) purchased from Qiagen (Valencia, CA, USA).
The mRNA level was estimated by RT-PCR in the linear range
of detection as follows. Reverse transcription was performed
with 4 μg total RNA using Oligo(dT) primers according to a
SuperScript™ II RT kit (catalogue number 18064-014;
GIBCO-BRL, Foster City, CA, USA). PCR amplification was
performed using the HotStarTaq Master Mix Kit (catalogue
number 203445; Qiagen). The PCR conditions were 95°C for
15 minutes for denaturation and then, depending on the differ-
ent primers, a variable number of cycles of 95°C for 1 minute,
63°C for 1 minute and 72°C for 1 minute, and a final extension
at 72°C for 10 minutes. The PCR products were fractionated
on 1.5% agarose gels containing ethidium bromide. The gels
were visualized under UV illumination and photographed by a
digital image capture system (KODAK 1D3.6; Digital Science,
Rochester, NY, USA).
Oligonucleotide primers were synthesized by Sigma-Genosys
(The Woodlands, TX, USA) as follows: pS2 gene (220 bp, 22
cycles), forward 5'-TTT GGA GCA GAG AGG AGG CAA
TGG-3' and reverse 5'-TGG TAT TAG GAT AGA AGC ACC
AGG G-3' ; ERα gene (650 bp, 35 cycles), forward 5'-TAC
TGC ATC AGA TCC AAG GG-3' and reverse 5'-ATC AAT
GGT GCA CTG GTT GG-3' ; and housekeeping gene glycer-
aldehyde-3-phosphate dehydrogenase (230 bp, 25 cycles),
forward 5'-TCA AGA AGG TGG TGA AGC AG-3' and
reverse 5'-CTT ACT CCT TGG AGG CCA TG-3'.
Immunoblotting
Cell lysate was prepared in radioimmunoprecipitation assay
buffer as described previously [26]. Supernatants after centrif-
ugation (14,000 × g, 20 min, 4°C) were recovered and the
protein content was quantified by the Lowry assay. Proteins
were size-separated by electrophoresis on SDS-PAGE gels
and were electroblotted onto nitrocellulose membranes.
Immunodetection was carried out with antibodies for ERα,
ERβ, and cyclin D1 purchased from Santa Cruz Biotechnology
Inc. (Santa Cruz, CA, USA) using enhanced chemofluores-
cence detection with a Storm machine (Molecular Dynamics,
Sunnyvale, CA, USA). Cleaved PARP as a marker of caspase-
mediated apoptosis, phospho-ERK1/2, total ERK1/2,
P21Cip1 and P27Kip1 were immunoblotted with antibodies
from Cell Signaling Technologies (Beverly, MA, USA). β-Actin
was detected as a protein loading control.
Estrogen receptor alpha nuclear/cytosol distribution
Subconfluent MCF-7 cells were incubated with PRF-IMEM
without serum and insulin for 48 hours to decrease back-
ground mitogen signaling. Fresh medium without or with 1 nM
17β-estradiol was added. Cells were harvested at differentBreast Cancer Research    Vol 9 No 6    Jiang et al.
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time points. Nuclear and cytosolic fractions were prepared
using NE-PER Nuclear and Cytoplasmic Extraction Reagents
kit (Pierce, Rockford, IL, USA) for western blot analyses. PARP
and α-tubulin were detected as markers of nuclear and cytosol
proteins, respectively. For testing the effect of decursin, estro-
gen-deprived MCF-7 cells were pre-treated with decursin for
2 hours and were stimulated with 1 nM 17β-estradiol for 1
hour (total decursin exposure time of 3 hours). The cells were
subjected to fractionation to yield nuclear and cytosolic frac-
tions for western blot analyses. Separate sets of flasks were
treated identically in parallel and used for total cell lysate prep-
aration for western blot analyses of the AR protein level.
Estrogen-response element transactivation
To determine the effects of decursin versus decursinol on the
transactivation of estrogen-response element (ERE) activity in
MCF-7 cells, we performed a transient transfection assay with
an ERE-luciferase report plasmid (a generous gift from Dr
Allen Gao, Roswell Park Cancer Institute, Buffalo, NY, USA)
[32]. An aliquot of 1 × 105 MCF-7 cells was placed in a 12-
well plate and co-transfected with 0.5 μg ERE-luciferase plas-
mid and 1.0 μg pSV-β-galactosidase reporter vector using jet-
PEI cationic polymer transfection reagent (Polyplus-
Transfection Inc. New York, NY, USA) in PRF-IMEM medium
without serum and insulin. After transfection for 24 hours, the
cells were treated with different concentrations of decursin,
decursinol or dimethylsulfoxide vehicle in the absence or pres-
ence of 1 nM 17β-estradiol. Cells extracts were prepared for
luciferase activity and β-galactosidase activity, and the luci-
ferase data were normalized to β-galactosidase.
Statistical evaluations
When appropriate and necessary, analyses of variance and
post-hoc comparisons (Bonferroni multiple comparison test)
were used to evaluate statistical significance.
Results
Growth inhibition of MCF-7 cells by decursin
To assess the effect of decursin on MCF-7 cell growth, we first
evaluated the cell number after 72 hours of treatment in com-
plete medium containing 10% FBS (T25 flasks, triplicate). As
shown in Figure 1b, decursin decreased the MCF-7 cell
number in a concentration-dependent manner (P < 0.01 for
20 μM, P < 0.001 for 50 μM and 100 μM). In a colony growth
assay of sparsely seeded cells, we detected cell colonies by
staining with diluted crystal violet after fixation (Figure 1c). The
number and size of crystal violet stainable colonies on day 7 of
treatment were substantially decreased by a single exposure
at 20 μM and higher concentrations (Figure 1c).
Requirement of side chain for cell-cycle arrest and 
apoptosis induction in estrogen-dependent and 
estrogen-independent breast cancer cells
To examine whether an induction of cell-cycle arrest and apop-
tosis contributed to the inhibition of breast cancer cell growth
by decursin, and to determine the chemical structure require-
ment for such activities, we evaluated the effects of decursin
and of its structural isomer DA versus decursinol in complete
medium on the cell-cycle distribution and apoptosis in MCF-7
cells (Figure 2) and in MDA-MB231 estrogen-independent
breast cancer cells (Figure 3).
When analyzed by flow cytometry at 24 hours of treatment
(Figure 2a), decursin and DA increased the G1-phase popula-
tion of MCF-7 cells and decreased the S-phase cells (G1
arrest) in the range of 10–50 μM in a concentration-depend-
ent manner (Figure 2a). ELISA detection of the apoptotic DNA
fragmentation at 24 hours (Figure 2b) as well as western blot
analysis for cleaved PARP at 48 hours of treatment (Figure 2c)
indicated increased caspase-mediated apoptosis at 50 μM
decursin or 50 μM DA in MCF-7 cells, in spite of a lack of cas-
pase-3 in these cells [33]. The cell-cycle arrest and apoptosis
effects were accompanied by decreased ERα abundance and
decreased ERK1/2 phosphorylation without changes of ERβ,
cyclin D1 and the two cyclin-dependent kinase inhibitor pro-
teins P21Cip1 and P27Kip1 (Figure 2c). The apoptosis could
be blocked by the pan-caspase inhibitor Q-VD-OPH, or could
be inhibited by the specific inhibitors of caspase 3/caspase 7,
caspase 8, and caspase 9 in MCF-7 cells (Figure 2d). Decurs-
inol at the tested concentrations, however, did not cause cell-
cycle arrest (Figure 2a) or cell death (Figure 2b,c) and caused
little or minimal changes in ERα abundance and ERK1/2 phos-
phorylation (Figure 2c).
For the estrogen-independent MDA MB-231 cells, decursin
and DA induced G1 arrest in the range 10–20 μM but induced
G2 arrest at 50 μM (Figure 3a). The G2 arrest effect was asso-
ciated with an increased abundance of the growth-inhibitory
ERβ protein and increased expression of P27Kip1 (Figure 3c).
This was consistent with the reported G2-arresting activity of
ERβ [34] and with P27Kip1 as a mediator of cell-cycle arrest
action of ERβ [35]. Decursinol, however, did not alter the cell-
cycle distribution pattern – except at 100 μM, a concentration
that increased G1-arrested cells (Figure 3a). Apoptosis was
induced in MDA MB-231 cells by decursin and DA, but
required at least twice as much of these compounds as in
MCF-7 cells (Figure 3b,c). The apoptotic events were associ-
ated not only with increased abundance of ERβ protein, but
also with a decreased phosphorylation of ERK1/2 and
decreased cyclin D1, and a paradoxical decrease of P21Cip1.
The caspase inhibitors blocked decursin-induced apoptosis in
MDA MB231 cells in the same fashion as in MCF-7 cells (data
not shown). Decursinol did not induce apoptosis at compara-
ble concentrations and caused a modest increase of ERβ pro-
tein and a decrease of pERK1/2 and P21Cip1 at an exposure
concentration of 100 μM, which induced G1 arrest.
Taken together, these results showed that the side chain on
decursin or DA was critical for the induction of cell-cycle
arrests and apoptosis in both breast cancer cell lines, regard-Available online http://breast-cancer-research.com/content/9/6/R77
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Figure 2
Apoptotic and cell-cycle effects of pyranocoumarins in MCF-7 cells Apoptotic and cell-cycle effects of pyranocoumarins in MCF-7 cells. (a) 
Cell-cycle distribution: cells were treated with decursin (D), decursinol 
angelate (DA) or decursinol (DL) at different exposure concentrations 
(10 μM, 20 μM, 50 μM) for 24 hours in complete medium. Bar height 
represents average of duplicate flasks, variation less than 2%. (b) 
Apoptotic DNA nucleosomes detected by the Death ELISA kit in MCF-
7 cells after 24 hours of treatment in complete medium. Bar height rep-
resents average of duplicate flasks, variation less than 2%. (c) Western 
blot analysis detection of cleaved poly(ADP-ribose) polymerase (c-
PARP), estrogen receptors (ERs) and selected mitogen signaling and 
cell-cycle regulator proteins after 48 hours of treatment in complete 
medium. (d) Inhibition of decursin (50 μM)-induced apoptosis by 10 
μM caspase inhibitors (CIs). PanI, Pan inhibitor (Q-VD-OPH); CI-3/7, 
zDEVDfmk; CI8, zIETDfmk; and CI9, zLEHDfmk (Enzyme Systems 
Products, Dublin, CA, USA). Inhibitors were added 2 hours prior to 
decursin treatment for an additional 24 hours. Mean ± standard devia-
tion, triplicate determinations.
Figure 3
Apoptotic and cell-cycle effects of pyranocoumarins on MDA-MB231  estrogen-independent breast cancer cells Apoptotic and cell-cycle effects of pyranocoumarins on MDA-MB231 
estrogen-independent breast cancer cells. (a) Cell-cycle distribution 
after 24 hours of treatment with decursin (D), decursinol angelate (DA) 
or decursinol (DL) at different exposure concentrations (10 μM, 20 μM, 
50 μM) in complete medium. Cells prepared as in Figure 2 for flow 
cytometric analysis. Bar height represents average of duplicate flasks, 
variation less than 2%. (b) Apoptosis detected by the DNA fragmenta-
tion Death ELISA kit in MDA-MB231 cells after 24 hours of treatment 
with different exposure concentrations (50 μM, 100 μM, 200 μM) in 
complete medium. (c) Western blot analysis detection of cleaved 
poly(ADP-ribose) polymerase (c-PARP), estrogen receptor (ER)β and 
selected mitogen signaling and cell-cycle regulator proteins after 48 
hours of treatment in complete medium.Breast Cancer Research    Vol 9 No 6    Jiang et al.
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less of their estrogen-dependence status. Moreover, the estro-
gen-dependent MCF-7 cells were more sensitive than the
estrogen-independent MDA-MB231 cells to the actions of
these effective compounds. The growth inhibitory effects
involved common pathways such as the inactivation of the
mitogen signaling ERK1/2, as well as distinct targets such as
ERα in MCF-7 cells, and ERβ and P27Kip1 in MDA-MB231
cells. In both cell lines, we did not detect an upregulation of
P21Cip1 protein in spite of cell-cycle arrests.
Effects of decursin or decursinol angelate on estrogen-
stimulated growth of MCF-7 cells
To specifically address the inhibitory activity of decursin or DA
on estrogen-stimulated cell growth, we seeded MCF-7 cells in
PRF-IMEM with charcoal-stripped FBS for 3 days to decrease
estrogen signaling, and then treated them with decursin, DA or
decursinol in the presence of 0.1 nM 17β-estradiol for 9 days.
Figure 4a shows representative wells from the different treat-
ments. Estrogen at this physiologically relevant concentration
stimulated the colony growth approximately twofold (Figure
4b, column 2 versus column 1; P < 0.01). The specificity of
estrogen signaling was verified by the steroidal pure antian-
drogen Faslodex™ [15,30,36-38] (Figure 4a, c versus b and
Figure 4b, columns 13 and 14 versus column 2; P < 0.0001)
and by the nonsteroidal partial antagonist 4-HT (Figure 4a, d
versus b and Figure 4b, columns 15 and 16 versus column 2;
P < 0.0001), which effectively inhibited the estrogen-stimu-
lated colony growth. Decursin (Figure 4a, e) and DA (Figure
4a, f) decreased estrogen-stimulated colony growth of MCF-7
cells with similar potency (Figure 4b, columns 3–5 and 6–9
versus column 2). Approximately 10 μM each of decursin and
DA was required to block the stimulated response by 0.1 nM
17β-estradiol (Figure 4b, columns 3 and 6 versus 2). Decurs-
inol, however, lacked any inhibitory activity within the concen-
tration range tested (Figure 4a, g and h versus b and Figure
4b, columns 9–12 versus column 2). Additional experiments
indicated even a mild stimulation effect ('agonist') of decursi-
nol in the absence of estrogen (data not shown).
To contrast the actions of decursin with the two well-charac-
terized antiestrogens, we analyzed MCF-7 cells treated with
decursin, Faslodex™ or 4-HT after 24 hours of estradiol stimu-
lation for ERα and for cleaved PARP by western blot analysis
(Figure 4c). Decursin caused a concentration-dependent
decrease of ERα protein with a reciprocal increase of the
cleaved PARP (Figure 4c, lanes 4 and 5 versus lane 2).
Faslodex™ (Figure 4c, lanes 6 and 7) effectively decreased
ERα abundance, and 4-HT (Figure 4c, lanes 8 and 9 versus
lane 2) increased the ERα level – both changes as expected
[15,37]. These latter two agents caused no increase in the
cleavage of PARP.
The ability for decursin and DA to downregulate ERα (Figure
4c) suggested mechanistic similarities with the pure antiestro-
gen Faslodex™ and distinctions from 4-HT. Indeed, results pre-
sented in Figure 4d show that decursin and Faslodex™
suppressed MCF-7 cell colony growth in an additive manner
in the absence (Figure 4d, columns 1–4) or in the presence
(Figure 4d, columns 5–8) of estradiol.
Since these results were consistent with an inhibition of estro-
gen-stimulated mitogenic signaling by decursin and DA, but
not by decursinol, we tested whether greater levels of estradiol
could overcome the inhibitory effects of decursin. Sparsely-
seeded MCF-7 cells in the absence or presence of 10 μM
decursin were treated with solvent vehicle or were stimulated
with 0.1 nM, 1 nM and 5 nM 17β-estradiol for 5 days. Estrogen
stimulation in the absence of decursin increased the colony
growth significantly in a concentration-dependent manner
(Figure 4e, columns 3, 5, and 7 versus column 1). Regardless
of the strength of estrogen stimulation (0.1–5 nM, a 50-fold
range), decursin inhibited the growth of MCF-7 cells (Figure
4e), producing a consistent relative inhibitory effect when nor-
malized to the respective estrogen dosages. These results
suggest that the action of decursin was probably not
accounted for as an antagonist competitor for estrogen ligand
binding to ERα.
Decursin and decursinol angelate suppressed ERα 
protein abundance, mRNA level and estrogen early 
signaling in MCF-7 cells
We subsequently focused on elucidating the mechanisms by
which the effective compounds affected ERα abundance and
signaling. Decursin and DA suppressed the ERα protein level
in MCF-7 cells in the absence or presence of estrogen stimu-
lation when treated for 48 hours in PRF-IMEM with charcoal-
stripped serum (Figure 5a).
An acute time-course experiment indicated that the downreg-
ulation of ERα occurred as early as after 6 hours of exposure
to decursin at a dose (50 μM) that increased PARP cleavage
(Figure 5a). This dose of decursin abolished the phosphoryla-
tive activation of ERK1/2 by estradiol, and abolished the
upregulation of the products of early estrogen-stimulated
genes such as cyclin D1 (early G1 phase) and c-Myc. The S-
phase-specific cyclin E was not affected, nor were the expres-
sion levels of P21Cip1 and P27Kip1 increased during this
timeframe by decursin.
To examine whether decursin increased ERα protein degrada-
tion, we blocked new protein synthesis in MCF-7 cells in com-
plete medium with cycloheximide (50 μg/ml) and analyzed the
ERα protein abundance by western blot analysis (Figure 5b).
The short-lived cyclin D1 was decreased by cycloheximide to
below the detection level (Figure 5b, lanes 5–8), affirming the
effectiveness of cycloheximide to block protein synthesis. The
level of ERα protein at 15 and 24 hours of cycloheximide treat-
ment (figure 5b, lanes 5 and 6) was further decreased by
decursin (figure 5b, lanes 9 and 10). The data were consistentAvailable online http://breast-cancer-research.com/content/9/6/R77
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Figure 4
Comparison of pyranocoumarins with antiestrogens Faslodex™ and 4-hydroxytamoxifen Comparison of pyranocoumarins with antiestrogens Faslodex™ and 4-hydroxytamoxifen. (a), (b) Effects of decursin (D) and decursinol angelate (DA) 
versus decursinol (DL) on estrogen-stimulated growth of MCF-7 cells as sparsely seeded colonies. MCF-7 cells (~10% confluent) were seeded in 
six-well plates in phenol-red free improved minimum essential medium (PRF-IMEM) with 5% charcoal-stripped serum without insulin with solvent, a 
pyranocoumarin or a known antiestrogen for 3 days. Without medium change, 0.1 nM 17β-estradiol (E2) was added for another 9 days. After fixation 
with 1% glutaraldehyde, the cells remaining attached were stained in situ with 0.02% crystal violet and photographed. (a) Image of representative 
wells. (b) Cell number estimated by dissolving the crystal violet in 70% ethanol (4 ml/well) and then optical density (OD) values measured at 570 nm 
with the reference filter of 405 nm. Results (mean ± standard error) represent triplicate wells. Analysis of variance (ANOVA): D at concentrations 
10–50 μM (D10-D50) versus (+)E2, P < 0.0001; DA10-DA50 versus (+E2), P < 0.0001; DL10-DL100 versus (+)E2, P > 0.5; Faslodex™ versus 
(+)E2, P < 0.0001; 4-hydroxytamoxifen (4-HT) versus (+)E2, P < 0.001. (c) Comparison of effects of D with those of Faslodex™ and 4-HT on ERα 
and cleaved poly(ADP-ribose) polymerase (c-PARP) in MCF-7 cells in the hormone deprivation/restimulation model. Fresh medium with 1 nM E2 
without or with D, or with known antiestrogen was replenished to respective flasks for 24 hours and the cellular extract analyzed by western blot. (d) 
Effect of combining D and Faslodex™ on basal and estrogen-stimulated colony growth in PRF-IMEM in six-well plates. Various treatments started at 
seeding for 5 days. Each bar represents mean ± standard error of the mean for triplicate wells. Results for one of two experiments, with identical pat-
terns of responses. Concentrations: D, 10 μM; Faslodex™, 0.1 nM; estradiol, 0.1 nM. Columns sharing the same letter are not different at P = 0.05. 
(e) Effect of D on colony growth of MCF-7 cells stimulated by increasing levels of estradiolin six-well plates. Various treatments started at seeding 
for 5 days. Each bar represents mean ± standard error of the mean for three independent experiments, each with duplicate or triplicate wells. D con-
centration, 10 μM. ANOVA: E2 effect, P < 0.001; D effect, P < 0.001; E2 × D interaction, P > 0.5.Breast Cancer Research    Vol 9 No 6    Jiang et al.
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with an enhanced degradation of ERα protein in decursin-
treated MCF-7 cells.
To determine whether decursin and DA affected the ERα
mRNA transcript abundance and to examine their impact on
transactivation of ERα-target genes, we examined the steady-
state mRNA level of ERα and the known estrogen-regulated
gene pS2 [39] using RT-PCR after cells had been exposed to
pyranocoumarin compounds for 24 hours (Figure 5c). As
expected, estrogen stimulation (Figure 5c, lane 2 versus lane
1) greatly increased the pS2 mRNA, and Faslodex™ (Figure
5c, lane 9 versus lane 2) blocked this estrogen-stimulated
change. Decursin or DA reduced the ERα mRNA abundance
in a concentration-dependent manner to below the basal level
(Figure 5c, lanes 3 and 4, lanes 5 and 6 versus lane 2). In con-
trast to the dramatic impact of decursin or DA on the ERα
mRNA level, the pS2  mRNA level was only modestly
decreased by decursin or DA. The ERα and pS2 mRNA levels
were not decreased by decursinol treatment (Figure 5c, lanes
7 and 8 versus lane 2).
In the time-course study (Figure 5d), the ERα mRNA level was
decreased by decursin (50 μM) exposure as early as 3 hours,
and the effect persisted through 12 hours. A suppressing
effect of this dose of decursin on the pS2 mRNA level was
detectable by 6 hours. Interestingly, the estrogen-stimulated
induction of the cyclin D1 mRNA level was decreased by
decursin only at the 3 hour timepoint. Combined, these data
Figure 5
Effects of pyranocoumarins on estrogen receptor alpha protein stability and mRNA level in MCF-7 cells Effects of pyranocoumarins on estrogen receptor alpha protein stability and mRNA level in MCF-7 cells. (a) Effect of decursin (D) and decursinol 
angelate (DA) on estrogen receptor (ER)α protein abundance in the absence and presence of estrogen. MCF-7 cells were cultured in phenol-red 
free improved minimum essential medium (PRF-IMEM) with 5% charcoal-stripped FBS (CSS) and without insulin for estrogen starvation for 3 days. 
For estrogen stimulation, D or DA was added 2 hours before 1 nM 17β-estradiol (E2) was added without medium change. Cell lysates were pre-
pared 48 hours after D or DA treatment for western blot analyses. In the time course, D and E2 treatments initiated simultaneously. c-PARP, 
poly(ADP-ribose) polymerase. (b) Effects of D (50 μM) on ERα protein stability in MCF-7 cells treated in complete medium with cycloheximide 
(CHX, 50 μg/ml) for 15, 24, 35, and 48 hours. Cell lysates analyzed by western blot for ERα and the short-lived cyclin D1 to establish potency of 
CHX. (c) Effects of D, DA and decursinol (DL) on the steady-state level of mRNA transcripts of ERα and the estrogen-responsive gene pS2 
detected by RT-PCR. MCF-7 cells were cultured in PRF-IMEM with 5% CSS and without insulin for estrogen starvation as above. D, DA, DL or 
Faslodex™ was added 2 hours before 1 nM E2 without medium change. After 24 hours, cells were harvested for RNA isolation and RT-PCR. The 
housekeeping glyceraldehyde-3-phosphate dehydrogenase (GAPDH) gene serves as a loading control. (d) Acute time-course effect of decursin on 
ERα and estrogen-responsive genes pS2 and cyclin D1 detected by RT-PCR. D and E2 treatments initiated simultaneously.Available online http://breast-cancer-research.com/content/9/6/R77
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suggest that decursin can downregulate ERα expression at
the transcriptional level as well as by post-translational
degradation.
Decursin increased ERα cytosol retention and inhibited 
transactivation of estrogen-response element
Because decursin and DA potently inhibit the cytosol to
nuclear translocation of AR upon androgen stimulation in pros-
tate cancer cells [26,27], we investigated whether a similar
inhibitory effect was exerted on ERα. We first determined the
optimal timeframe to study ERα nuclear translocation in MCF-
7 cells. As shown in Figure 6a (lane 2 versus lane 1), the ERα
was predominantly localized in the nucleus in MCF-7 cells
grown in PRF-IMEM medium without serum and insulin for 48
hours. This was in contrast to the predominant cytosolic
distribution of AR in androgen-deprived prostate cancer cells
Figure 6
Effects of pyranocoumarins on estrogen receptor alpha nuclear translocation and transactivation in MCF-7 cells Effects of pyranocoumarins on estrogen receptor alpha nuclear translocation and transactivation in MCF-7 cells. (a), (b) Inhibitory effects of decursin 
on estrogen receptor (ER)α nuclear translocation in MCF-7 cells. (a) The time course of ERα nuclear translocation in MCF-7 cells stimulated by 17β-
estradiol (E2) was first established in estrogen-starved MCF-7 cells. Fresh medium without or with 1 nM E2 was added. At different time points, 
nuclear (N) and cytosolic (C) fractions were prepared for western blot analyses. Poly(ADP-ribose) polymerase (PARP) and α-tubulin were detected 
as markers of N and C proteins, respectively. DMSO, dimethylsulfoxide. (b) For the decursin experiment, estrogen-deprived MCF-7 cells were pre-
treated with decursin for 2 hours and were stimulated with 1 nM E2 for 1 hour (total decursin exposure time, 3 hours). N and C fractions were pre-
pared for western blot analyses. One-tenth nuclear fraction was used compared with the time-course experiment to show the difference. The total 
lysate ERα level was determined (right panel). (c) Differential effects of decursin versus decursinol on estrogen-response element (ERE) activity in 
MCF-7 cells: left, with E2; right, without, E2. An aliquot of 1 × 105 MCF-7 cells was placed in a 12-well plate and cotransfected with ERE-luciferase 
reporter plasmid and pSV-β-galactosidase reporter in phenol-red free improved minimum essential medium (PRF-IMEM) without serum and insulin. 
After transfection for 24 hours, the cells were treated with different concentrations of decursin (D, 20 μM, 50 μM), decursinol (DL, 100 μM) or 
DMSO in the absence or presence of 1 nM E2 for 24 hours. Cells extracts were prepared for luciferase activity and β-galactosidase activity. Mean ± 
standard error, three independent experiments. *P < 0.05, **P < 0.01, ***P < 0.001 versus basal or E2-stimulated control.Breast Cancer Research    Vol 9 No 6    Jiang et al.
Page 10 of 12
(page number not for citation purposes)
[26]. Nevertheless, a decrease of cytosolic ERα (Figure 6a,
lane 3 versus lane 1) and a reciprocal increase of nuclear ERα
(Figure 6a, lane 4 versus lane 2) could be detected as soon as
30 minutes of stimulation by 17β-estradiol, and the changes
persisted through 4 hours of stimulation (Figure 4a).
For experiments with decursin or Faslodex™, we pretreated
estrogen-deprived MCF-7 cells for 2 hours with these agents
and then stimulated with 1 nM 17β-estradiol for 1 hour (total
decursin exposure time of 3 hours). We used one-tenth of the
nuclear extract of that used in the time-course experiment to
increase the sensitivity to detect a difference in the nuclear
ERα abundance. The results showed that decursin prevented
the cytosolic decrease of ERα induced by 17β-estradiol
(Figure 6b, lanes 3 and 4 versus lane 2), and dampened the
increase in nuclear ERα in a reciprocal manner (Figure 6b,
lanes 8 and 9 versus lane 7). In contrast, Faslodex™, as
expected [15], induced a sharp decrease of the cytosolic ERα
as well as the nuclear ERα (Figure 6b, lanes 5 and 10). The
reduction of ERα induced by Faslodex™ was reflected in the
total cell lysate (Figure 6b, lane 15 versus lanes 11 and 12).
To further evaluate the effect of decursin on ERα transactiva-
tion of estrogen-stimulated genes, we used a transient trans-
fection assay with luciferase reporter plasmid driven by
multiple copies of the ERE [32]. The reporter assay showed a
dramatic activation of ERE-promoter activity by 17β-estradiol
(~25-fold) (Figure 6c, column 2 versus column 1). Decursin
caused a concentration-dependent decrease of estrogen-
stimulated ERE transactivation (Figure 6c, columns 3 and 4
versus column 2). Decursinol, in contrast, exerted a moderate
inhibition of the estrogen-stimulated transcription (Figure 6c,
column 5). In the absence of 17β-estradiol, however, decursi-
nol had a very mild stimulation effect on basal ERE activity (Fig-
ure 6c, column 9 versus column 6) whereas decursin lacked
such an 'agonist' effect (Figure 6c, columns 7 and 8 versus
column 6).
Discussion
In the present study we examined the growth inhibitory effects
of decursin and DA on two human breast cancer cell lines, and
the probable mechanisms, to provide a scientific rationale to
support the potential utility of these compounds and/or their
derivatives as breast cancer chemopreventive agents. A
number of significant and novel findings in the present study
are worthy of further comment.
The first observation is the structural basis for the in vitro
breast cancer growth inhibitory effects of decursin and its nat-
ural analogs. We found that decursin and DA, structural iso-
mers on the side chain (Figure 1a), exerted comparable
potency in terms of cell-cycle arrest (Figures 2a and 3a), apop-
tosis induction (Figures 2b,c and 3b,c) and impact on selected
molecular targets, such as inactivation of ERK1/2 (Figures 2c
and 3c), in both MCF-7 cells and MDA-MB231 cells. Decurs-
inol, without the side chain, lacked these effects at compara-
ble concentrations. These results are consistent with the
structure-activity patterns reported for decursin and DA to
inhibit androgen/AR signaling and to induce cell-cycle arrest
and apoptosis in prostate cancer cells [27]. These studies
together support the critical requirement of the side chain
attached to the pyranocoumarin core structure to exert these
diverse actions related to steroid hormone signaling as well as
cell-cycle arrest and proapoptotic pathways.
Second, the inhibitory actions reported here for decursin and
DA against estrogen-induced signaling events and cell prolif-
eration in the MCF-7 cell model highlight potential specificity
for these compounds to attenuate breast cancer risk in pre-
menopausal women. In addition, the observed cell-cycle arrest
and apoptotic effects of these two compounds on MDA-
MB231 cells suggest that these agents may also be useful for
the control of estrogen-independent breast cancer growth. In
MCF-7 cells, the agents' effects on the cell cycle and
apoptosis were associated with decreased ERα abundance;
in MDA-MB231 cells, their effects on cell-cycle arrest and
apoptosis were closely accompanied by an induction of ERβ
and a paradoxical loss of P21Cip1 expression. Decursinol
exerted minimal effect on these molecules. Although both
receptors are capable of regulating gene transcription through
binding the ERE, ERα and ERβ have been shown to be differ-
entially activated by various ligands [7,8] – whereas ERα is
able to regulate endogenous genes in a ligand-dependent
manner, ectopically expressed ERβ has been shown to inhibit
MDA MB-231 cell proliferation in response to added estrogen
[8]. A study has shown that the forced expression of ERβ in
breast cancer cells inhibits their growth in vitro through an
induction of G2 arrest [34]. A recent paper showed that an
inducible expression of ERβ through a Tet-Off system in vivo
potently inhibited the growth of T47D xenograft and angiogen-
esis [40]. Whether ERβ induction by these compounds is
restricted to estrogen-independent breast cancer cells and
the significance of this induction in growth arrest induced by
decursin or DA await further analyses.
Third, comparison of the actions of decursin and DA with
those of Faslodex™ and 4-HT in MCF-7 cells revealed both
similar and distinct mechanisms from these well-characterized
antiestrogens to inhibit estrogen-stimulated growth (Figures
4c and 5c). Tamoxifen is a triphenylethylene antiestrogen with
partial ER agonist activity and has been used for a couple of
decades for the classic hormonal treatment of breast cancers
expressing ERs [14,15]. In spite of its partial agonist activity,
tamoxifen has been approved for use as chemopreventive
agent for breast cancer in high-risk women [14]. On the other
hand, ICI 182,780 (now called fulvestrant or Faslodex™) is the
only steroidal antiestrogen that has reached clinical develop-
ment. Both compounds are competitive inhibitors for the bind-
ing of 17β-estradiol to ERα, but their mechanisms of action are
quite different. Tamoxifen inhibits the activation function 2 ofAvailable online http://breast-cancer-research.com/content/9/6/R77
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ERα-mediated transactivation, probably via the recruitment of
corepressors. Yet this type of antagonist does not interfere
with the activation function 1-mediated transactivation of ERα.
Tamoxifen and its active metabolite 4-HT have also been
known to cause ER nuclear accumulation. By contrast, Faslo-
dex™ suppresses both activation function 1 and activation
function 2 ERα transactivation functions, and prevents nuclear
transport of the receptor. In addition, Faslodex™ reduces the
half-life of ER protein, leading to receptor content downregu-
lation [15,37].
Decursin shares some mechanisms of actions with Faslodex™,
including a downregulation of the ERα protein level (Figures
4c and 5a) through increased protein degradation (Figure 5b)
and decreased abundance of ERα mRNA (Figure 5c). Further-
more, decursin (Figures 4d,e and 6c) and DA (data not shown)
did not exert any 'agonist' activity in the absence of estrogen.
Such a property is desirable for breast cancer prevention in
contrast to tamoxifen, which exerts a partial agonist activity,
and its long-term use increases the risk of endometrial cancer
[10,11,14]. At the molecular target level, decursin differed
from the active tamoxifen metabolite 4-HT, which increased
ERα protein abundance (Figure 4c) as has been well docu-
mented [14,15].
Fourth, the present study extended our understanding of the
inhibitory actions of decursin and DA on sex steroid receptor
signaling from prostate cancer cells to breast cancer cells.
Similarities include observations that these agents inhibit the
ligand-induced nuclear translocation of ERα (Figure 6b) and
AR [26,27], induce an increased degradation of ERα (Figure
5b) as well as AR [27], and attenuate their transactivation of
respective promoter sequences (Figure 6c) [27]. In contrast to
the lack of any impact by decursin or DA on the AR mRNA
level in LNCaP cells [26,27], however, a sharp and rapid
downregulation of ERα  mRNA by these compounds was
observed in MCF-7 cells (Figure 5c), suggesting different
pathways were targeted in organ-specific ways.
Conclusion
In summary, our data provide support for decursin and DA as
potential novel breast cancer chemopreventive agents by tar-
geting ERα signaling through inhibiting its transcription, stabil-
ity and abundance as well as nuclear translocation in
estrogen-dependent MCF-7 cells, and by inducing ERβ in
estrogen-independent MDA-MB231 cells, leading to cell-
cycle arrest and proapoptotic actions. In both cell lines,
decreased ERK1/2 phosphorylation was associated with
these cellular effects, whereas the effects of these com-
pounds on cell-cycle regulatory proteins cyclin D1, P21CIP1
and P27KIP1 appeared cell line specific. Our data suggest
that these agents may also be used in combination with exist-
ing antiestrogen drugs such as Faslodex™ and tamoxifen to
increase preventive efficacy and to decrease unwanted side
effects.  In vivo validation of the agents' breast cancer
preventive and treatment efficacy in preclinical animal models
is warranted.
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